Q-omics provides the consensus-scored PDP2 profile across patient tissues and cancer cell-line models. PDP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDP2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PDP2 RNA expression shows 20,050 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where PDP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDP2 survival associations across molecular data types. PDP2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDP2 RNA expression–survival associations across cancer types. High PDP2 expression shows unfavorable associations in ACC and LIHC, but favorable associations in KIRC, READ, LGG and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDP2 RNA expression.
This table summarizes PDP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDP2 shows lower tumor expression in KIRC, THCA and BRCA and higher tumor expression in BLCA, HNSC and LIHC. The KIRC box plot shows higher PDP2 RNA expression in normal versus tumor tissue (log2 FC = −1.218, t-test p < 0.001).
This table shows molecular features associated with PDP2 in patient tissues and cancer cell lines. In patient samples, PDP2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
